The role of biomarkers for starting antifungals in the intensive care unit

Clinical Pulmonary Medicine

Volumn 22, Issue 6, 2015, Pages 286-293

  Pagani, Jean Luc ^a   Revelly, Jean Pierre ^a   Que, Yok Ai ^a   Eggimann, Philippe ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Betaglucan; Bimoarkers; Candida albicans; Candidemia; Procalcitonin

Indexed keywords

ANTIFUNGAL AGENT; BIOLOGICAL MARKER; FUNGAL DNA; FUNGUS ANTIBODY; MANNAN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CRITICALLY ILL PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; META ANALYSIS (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURGICAL PATIENT; SYSTEMATIC REVIEW (TOPIC);

EID: 84946727906     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000118     Document Type: Article

References (61)

1. Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(suppl 7):53-67.
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427-431.
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
4. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(suppl 79):19-37.
5. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 2004;38:311-320.
6. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612-1618.
7. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-2329.
8. Kett DH, Azoulay E, Echeverria PM, et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665-670.
9. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695-1703.
10. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
11. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
12. Azoulay E, Dupont H, Tabah A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med. 2012;40:813-822.
13. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745-4752.
14. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532-538.
15. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33:1959-1967.
16. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-758.
17. Montravers P, Dupont H, Eggimann P. Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis. Intensive Care Med. 2013;39:2226-2230.
18. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014;40:1429-1448.
19. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685-702.
20. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003;29:2162-2169.
21. Charles PE, Dalle F, Aube H, et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005;31:393-400.
22. Eggimann P, Calandra T, Fluckiger U, et al. Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med. 2005;31:1514-1521.
23. Solomkin JS, Flohr AB, Quie PG, et al. The role of Candida in intraperitoneal infections. Surgery. 1980;88:524-530.
24. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-1072.
25. Senn L, Eggimann P, Ksontini R, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med. 2009;35:903-908.
26. Tissot F, Lamoth F, Hauser PM, et al. Beta-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013;188:1100-1109.
27. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3:772-785.
28. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011;1:1-37.
29. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665-670.
30. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18(suppl 7):9-18.
31. Chang SS, Hsieh WH, Liu TS, et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PloS One. 2013;8:e62323.
32. Mikulska M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222.
33. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1- > 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-659.
34. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878-885.
35. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240-1248.
36. Lamoth F, Cruciani M, Mengoli C, et al. Beta-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-643.
37. Takesue Y, Kakehashi M, Ohge H, et al. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg. 2004;28:625-630.
38. Mohr JF, Sims C, Paetznick V, et al. Prospective survey of (1- > 3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol. 2011;49:58-61.
39. Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1- > 3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15:R249.
40. Del Bon V, Delfino E, Furfaro E, et al. Clinical performance of the (1,3)-beta-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol. 2011;18:2113-2117.
41. Leon C, Ruiz-Santana S, Saavedra P, et al. Value of beta-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med. 2012;38:1315-1325.
42. Lo Casico G, Koncan R, Stringari G, et al. Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit. Eur J Clin Microbiol. 2015;34:357-365.
43. Fortun J, Meije Y, Buitrago MJ, et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. J Antimicrob Chemother. 2014;69:3134-3141.
44. Hanson KE, Pfeiffer CD, Lease ED, et al. beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PloS One. 2012;7:e42282.
45. Zaragoza R, Peman J, Quindos G, et al. Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microb Infect. 2009;15:592-595.
46. Peman J, Zaragoza R, Quindos G, et al. Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients. BMC Infect Dis. 2011;11:60.
47. Charles PE, Dalle F, Aho S, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med. 2006;32:1577-1583.
48. Martini A, Gottin L, Menestrina N, et al. Procalcitonin levels in surgical patients at risk of candidemia. J Infect. 2010;60:425-430.
49. Brodskà H, Malickova K, Adamkova V, et al. Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med. 2013;13:165-170.
50. Cortegiani A, Russotto V, Montalto F, et al. Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol. 2014;14:9.
51. Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care. 2010;16:465-469.
52. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730-737.
53. Charles PE, Castro C, Ruiz-Santana S, et al. Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med. 2009;35:2146-2150.
54. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235-243.
55. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271-276.
56. Ostrosky-Zeichner L, Aranah L, Eggimann P, et al. Preliminary Results of a Multicenter, International, Retrospective, Study to Validate a Clinical Prediction Rule (CPR) to Identify Critically-ill Patients at Risk of Invasive Candidiasis (IC) for TReatment with Empirical Antifungal Therapy (TREAT Study). Chicago, IL: ICAAC; 2008.
57. Ostrosky-Zeichner L, Pappas PG, Shoham S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54:46-51.
58. Hermsen ED, Zapapas MK, Maiefski M, et al. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care. 2011;15:R198.
59. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624-1633.
60. Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58:1219-1226.
61. Montravers P, Mira JP, Gangneux JP, et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061-1067.